Vaillancourt Régis, Gallagher Shannon, Cameron Jameason D, Dhalla Rahim
Department of Pharmacy, Children's Hospital of Eastern Ontario, Ottawa.
Hybrid Pharm, Ottawa, Ontario.
Can Pharm J (Ott). 2022 Apr 15;155(3):175-180. doi: 10.1177/17151635221089617. eCollection 2022 May-Jun.
Medical cannabis has been increasingly used in Canada after being sanctioned by Health Canada in 2001. Insomnia and sleep disorders are among the most common conditions for which patients report using cannabis. Current research shows cannabis may have a beneficial effect in sleep disorders and may improve patient-reported sleep scores.
A retrospective chart review was conducted at Hybrid Pharm community pharmacy in Ottawa, Ontario, and included patients who were interested in, or already using, medical cannabis for sleep disorders. A qualitative, exploratory approach was taken to evaluate the descriptive efficacy and safety of medical cannabis when prescribed for insomnia or comorbid conditions. The comprehensive data collection also involved investigating the impact of cannabis on other medication used for insomnia.
A total of 38 patients were identified as having adequate follow-up documentation to assess the impact of medical cannabis. At time of data collection, 15 patients (39%) were able to reduce or completely discontinue a prescription medication indicated for sleep. On follow-up, 27 patients (71%) reported a subjective improvement in their sleep or related condition. Only 8 patients (21%) reported any adverse effects from medical cannabis use, and these were manageable and did not require discontinuation of cannabis.
This study highlights the importance of a pharmacist's role in the management of cannabis-based therapy, including ongoing supportive care, follow-up and medication management. 2022;155:xx-xx.
自2001年获得加拿大卫生部批准后,医用大麻在加拿大的使用日益增多。失眠和睡眠障碍是患者报告使用大麻治疗的最常见病症。目前的研究表明,大麻可能对睡眠障碍有有益作用,并可能改善患者报告的睡眠评分。
在安大略省渥太华的Hybrid Pharm社区药房进行了一项回顾性病历审查,纳入了对医用大麻治疗睡眠障碍感兴趣或已经在使用医用大麻的患者。采用定性、探索性方法评估医用大麻用于治疗失眠或合并症时的描述性疗效和安全性。全面的数据收集还包括调查大麻对其他用于治疗失眠的药物的影响。
共确定38例患者有足够的随访记录以评估医用大麻的影响。在收集数据时,15例患者(39%)能够减少或完全停用一种用于睡眠的处方药。随访时,27例患者(71%)报告其睡眠或相关病症有主观改善。只有8例患者(21%)报告使用医用大麻有任何不良反应,且这些反应可控,无需停用大麻。
本研究强调了药剂师在基于大麻的治疗管理中的作用的重要性,包括持续的支持性护理、随访和药物管理。2022;155:xx - xx。